Entamoeba histolytica

From WikiMD's WELLNESSPEDIA

Entamoeba histolytica is a protozoan parasite responsible for a disease known as amoebiasis. This single-celled organism primarily infects humans and other primates. Although it is found worldwide, it is most prevalent in tropical regions with poor sanitary conditions.

Life Cycle[edit]

The life cycle of Entamoeba histolytica involves two stages: the trophozoite and the cyst. The trophozoite is the active, feeding, and dividing stage, while the cyst is the dormant, non-feeding, and infective stage. The cysts are excreted in the feces of an infected individual and can survive in the environment for weeks. If ingested by another individual, the cysts transform into trophozoites in the small intestine and then migrate to the large intestine.

Pathogenesis[edit]

Entamoeba histolytica causes disease by invading the intestinal wall, causing ulceration and inflammation. In severe cases, the amoebae can penetrate the intestinal wall and spread to other organs, primarily the liver, causing amoebic liver abscess.

Diagnosis and Treatment[edit]

Diagnosis of Entamoeba histolytica infection is made by identifying the parasite in stool samples. Treatment typically involves antiprotozoal drugs such as metronidazole.

Prevention[edit]

Prevention of Entamoeba histolytica infection primarily involves improved sanitation and hygiene practices, including proper disposal of human feces, protection of food and water supplies from contamination, and careful handwashing.

See Also[edit]













Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.